Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekter af 5-Methyltetrahydrofolsyre-tilskud på moders sundhed og en-kulstofstofskifte under amning (OCMS)

10. november 2026 opdateret af: Fundació Sant Joan de Déu

Effekter af 5-Methyltetrahydrofolsyre-tilskud på moders sundhed og enkulstofmetabolisme under amning

This double-blind, randomized, placebo-controlled parallel trial evaluates the effects of maternal 5-methyltetrahydrofolate (5-MTHF) supplementation during breastfeeding. Thirty-six lactating mother-infant dyads will be randomized (1:1) to receive 5-MTHF or placebo for 6 weeks, stratified by infant sex and mode of delivery. Tolerability and adverse events will be monitored.

Pre- and post-intervention assessments include breast milk one-carbon metabolites and oligosaccharides; maternal plasma one-carbon metabolites and metabolic health markers. Maternal mental health will be evaluated using the SCL-90-R questionnaire. A follow-up visit at 4 months will reassess infant anthropometry and microbiome outcomes.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

36

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Marta Ramon Krauel, MD PhD
  • Telefonnummer: Ext. 71263 (+34) 93 280 40 00
  • E-mail: marta.ramon@sjd.es

Studiesteder

    • Barcelona
      • Barcelona, Barcelona, Spanien, 08950
        • Rekruttering
        • Hospital Sant Joan de Deu
        • Kontakt:
      • Barcelona, Barcelona, Spanien, 08950
        • Ikke rekrutterer endnu
        • Hospital Sant Joan de Déu
        • Kontakt:
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 42 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Maternal age between 18 and 42 years
  • Gestational age at birth ≥ 37 weeks.
  • Exclusive breastfeeding at enrollment.
  • Infant age 0-1 months

Exclusion Criteria:

  • Multiple pregnancy
  • Presence of disease or malformations in the infant.
  • Weight-Standard Deviation Score < -1 at enrollment.
  • Use of folate-containing multivitamin supplements during breastfeeding

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Placebo

Matching placebo administered daily for 6 weeks during lactation.

Eksperimentel: 5-MTHF Supplementation

Dietary Supplement (5-MTHF)

Oral supplementation with 5-MTHF (800 µg) administered daily for 6 weeks during lactation.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Adverse Events
Tidsramme: Baseline, 6 weeks, 4 months

Treatment safety and tolerability will be evaluated by assessing differences in the incidence of potential adverse events between groups, focusing on gastrointestinal symptoms.

Baseline, 6 weeks, 4 months
Change in breast milk 5-MTHF concentration
Tidsramme: Baseline, 6 weeks

Change in breast milk 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks.

Baseline, 6 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in plasma 5-MTHF concentration
Tidsramme: Baseline, 6 weeks

Change in maternal plasma 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks.

Baseline, 6 weeks
Change in breast milk one-carbon metabolite concentration
Tidsramme: Baseline, 6 weeks

Change in breast milk one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks.

Baseline, 6 weeks
Change in plasma one-carbon metabolite concentration
Tidsramme: Baseline, 6 weeks

Change in plasma one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks.

Baseline, 6 weeks
Change in Human Milk Oligosaccharide (HMO) concentration
Tidsramme: Baseline, 6 weeks

Change in HMO concentrations between Baseline and 6 weeks

Baseline, 6 weeks
Change in Maternal Plasma Glucose Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal blood glucose levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Plasma Glycated Hemoglobin (HbA1c) Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal blood glycated hemoglobin (HbA1c) between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Plasma Insulin Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal blood insulin levels between Baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Plasma Triglyceride (TAG) Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal blood triglyceride (TAG) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Total Cholesterol Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal blood total Cholesterol levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood LDL Cholesterol Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal low-density lipoprotein (LDL) cholesterol levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood HDL Cholesterol Concentration
Tidsramme: Baseline, 6 weeks

Change in maternal high-density lipoprotein (HDL) cholesterol levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Alanine Aminotransferase (ALT) Levels
Tidsramme: Baseline, 6 weeks

Change in maternal alanine aminotransferase (ALT) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Aspartate Aminotransferase (AST) Levels
Tidsramme: Baseline, 6 weeks

Change in maternal aspartate aminotransferase (AST) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Gamma-Glutamyl Transferase (GGT) Levels
Tidsramme: Baseline, 6 weeks

Change in maternal gamma-glutamyl transferase (GGT) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Symptom Checklist-90-Revised (SCL-90-R) scale
Tidsramme: Baseline, 3 weeks

The SCL-90-R is a 90-item self-report questionnaire assessing psychological symptoms over the past week, with a range of 0-90 across 9 dimenions: Somatization, Obsessive-compulsive, Interpersonal sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation, Psychoticism. Higher scores indicate worse outcome.

Baseline, 3 weeks
Change in infant BMI z-score
Tidsramme: Baseline, 6 weeks

We will measure infant body weight, length, and head circumference to calculate BMI z-scores according to WHO growth standards, and changes between baseline, 6 weeks and 4 months will be assessed.

Baseline, 6 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Maternal and infant gut microbiome composition
Tidsramme: Baseline, 6 weeks

Bacterial DNA will be isolated from infant and maternal fecal samples and sequenced to obtain microbiome composition.

Baseline, 6 weeks
Maternal plasma and breast milk metabolomic profile
Tidsramme: Baselina, 6 weeks

The metabolomic profile will be obtained with the Biocrates Quant 1000 kit from plasma and breast milk samples.

Baselina, 6 weeks
Milk imprinted protein levels
Tidsramme: Baseline, 6 weeks

Imprinted proteins in human milk samples will be analyzed by ELISA.

Baseline, 6 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Carles Lerin, PhD, Fundació Sant Joan de Déu

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. april 2026

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

30. april 2027

Datoer for studieregistrering

Først indsendt

19. marts 2026

Først indsendt, der opfyldte QC-kriterier

27. marts 2026

Først opslået (Faktiske)

2. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • PIC-143-25

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .